临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
cytogenetics for diagnosis and prediction,307–308,314–315 315
Chronic myeloid leukemia (CML)clinical features,293–294 294
cytogenetics for diagnosis and prediction,304–305 305
toxicity as basis for exclusion,74–76 76
Expanded Disability Status Scale (EDSS),360–361,406–407 407
Atherosclerosis C-reactive protein as biomarker,349–351 351
5-Aza-deoxycytidine myelodysplastic syndrome management,299 299
Bacillus Calmette-Guerin (BCG),490 490
Baker v. St. Agnes Hospital,569 569
BCR-ABL see Philadelphia chromosome Bedikian study,234–235 235
Berthold study,148–149 149
Biomarkers breast cancer,332–337 337
C-reactive protein see C-reactive protein circulating tumor cells,338 338
colorectal cancer,337–340 340
DNA microarray colon cancer,343–344 344
hepatocellular carcinoma,344–345 345
ovarian cancer,342–343 343
hepatitis C virus infection,381–382 382
mass spectrometry,349 349
measurement relative to chemotherapy,322 322
predictive versus prognostic,328–330 330